What is the recommended dose of tremfya for plaque psoriasis?

Recommended dose of Tremfya for plaque psoriasis

Tremfya (guselkumab) is given by subcutaneous injection. The standard schedule starts with a 100 mg dose at week 0, a second 100 mg dose at week 4, and then 100 mg every 8 weeks thereafter.

How long does it take for Tremfya to start working for plaque psoriasis
Clinical studies show measurable skin improvement as early as week 4, with most patients reaching clear or almost clear skin by week 16.

What happens if a dose is missed
If a dose is missed, it should be given as soon as possible, then the regular 8-week schedule resumes from the date of the missed injection.

Can the dose be adjusted for body weight or kidney function
No dose adjustment is required for body weight, age, or mild-to-moderate kidney or liver impairment. The 100 mg dose remains the same for all adult patients.

How does Tremfya compare with other IL-23 inhibitors for psoriasis
Tremfya and Skyrizi both target IL-23 and use 100 mg dosing, but Tremfya is given every 8 weeks after the first two doses, while Skyrizi is given every 12 weeks after the loading doses.

When does the Tremfya patent expire
The main U.S. patent covering guselkumab expires in 2031, with additional patents extending protection into the mid-2030s; biosimilar entry is not expected until at least 2032.

Who makes Tremfya and how is it supplied
Janssen Biotech manufactures Tremfya. It comes as a single-use prefilled syringe or One-Press injector, each containing 100 mg in 1 mL solution.

What side effects are patients most concerned about
Upper-respiratory infections, headache, and injection-site reactions are the most frequently reported side effects. Serious infections and allergic reactions remain rare but are monitored in patients with active infection or a history of tuberculosis.

DrugPatentWatch.com